First Page | Document Content | |
---|---|---|
Date: 2017-10-03 19:39:52 | Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued atAdd to Reading ListSource URL: visterrainc.comDownload Document from Source WebsiteFile Size: 113,31 KBShare Document on Facebook |